Literature DB >> 22977637

Sulfotransferase 1A1 Arg(213)His polymorphism and prostate cancer risk.

Serdal Arslan1, Yavuz Silig, Hatice Pinarbasi.   

Abstract

Sulfotransferase 1A1 (SULT1A1) is a member of the sulfotransferase family that plays an important role in the biotransformation of numerous carcinogenic and mutagenic compounds through sulfation. A transition, G to A at position 638, in the SULT1A1 gene, results in the Arg(213)His change. This single nucleotide polymorphism reduces the activity and thermostability of the SULT1A1 enzyme. In the present study, the relationship between the SULT1A1 Arg(213)His polymorphism and prostate cancer was investigated using PCR-RFLP. No significant difference in genotype and allele distribution was noted between the prostate cancer and control populations (P=0.072; P=0.099, respectively). The risk of prostate cancer in individuals carrying the SULT1A1(*)2 allele (His(213) allele) was determined by combining the SULT1A1(*)1/SULT1A1(*)2 (Arg/His(213)) and SULT1A1(*)2/SULT1A1(*)2 (His/His(213)) genotypes. No association was observed between SULT1A1 Arg(213)His polymorphism and prostate cancer incidence (P=0.24; OR, 1.36; 95% CI, 0.84-2.25). However, the His(213) allele was found to increase the risk of prostate cancer by 1.36-fold. In smoker and non-smoker populations, no significant relationship was determined between the prostate cancer and control population (P=0.45; P=0.34, respectively).

Entities:  

Year:  2011        PMID: 22977637      PMCID: PMC3440825          DOI: 10.3892/etm.2011.334

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  24 in total

1.  Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain.

Authors:  K Richard; R Hume; E Kaptein; E L Stanley; T J Visser; M W Coughtrie
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

2.  Phenol sulphotransferase SULT1A1 polymorphism in prostate cancer: lack of association.

Authors:  M Steiner; M Bastian; W A Schulz; T Pulte; K H Franke; A Röhring; J M Wolff; H Seiter; P Schuff-Werner
Journal:  Arch Toxicol       Date:  2000-07       Impact factor: 5.153

3.  The relationship among the polymorphisms of SULT1A1, 1A2 and different types of cancers in Taiwanese.

Authors:  Ching-Tien Peng; Jui-Chang Chen; Kun-Tu Yeh; Yu-Feng Wang; Ming-Feng Hou; Tai-Ping Lee; Mu-Chih Shih; Jan-Yi Chang; Jan-Gowth Chang
Journal:  Int J Mol Med       Date:  2003-01       Impact factor: 4.101

4.  Genetic polymorphisms and linkage disequilibrium of sulfotransferase SULT1A1 and SULT1A2 in a Korean population: comparison of other ethnic groups.

Authors:  Kyoung-Ah Kim; Sook-Young Lee; Pil-Whan Park; Jong-Myung Ha; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2005-08-26       Impact factor: 2.953

Review 5.  Current status of the cytosolic sulfotransferases in the metabolic activation of promutagens and procarcinogens.

Authors:  E Banoglu
Journal:  Curr Drug Metab       Date:  2000-07       Impact factor: 3.731

Review 6.  Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.

Authors:  L W Wormhoudt; J N Commandeur; N P Vermeulen
Journal:  Crit Rev Toxicol       Date:  1999-01       Impact factor: 5.635

7.  Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rats: dose-response studies.

Authors:  T Shirai; S Tamano; M Sano; T Masui; R Hasegawa; N Ito
Journal:  Princess Takamatsu Symp       Date:  1995

8.  Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population.

Authors:  Yavuz Silig; Hatice Pinarbasi; Sezgin Günes; Semih Ayan; Hasan Bagci; Oge Cetinkaya
Journal:  Cancer Invest       Date:  2006-02       Impact factor: 2.176

Review 9.  Cancer of the prostate.

Authors:  D P Dearnaley
Journal:  BMJ       Date:  1994-03-19

10.  Activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b] pyridine by cDNA-expressed human and rat arylsulfotransferases.

Authors:  S Ozawa; H C Chou; F F Kadlubar; K Nagata; Y Yamazoe; R Kato
Journal:  Jpn J Cancer Res       Date:  1994-12
View more
  5 in total

Review 1.  Sulfotransferase genetic variation: from cancer risk to treatment response.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Drug Metab Rev       Date:  2013-09-06       Impact factor: 4.518

2.  Pharmacogenetics of SULT1A1.

Authors:  Jaclyn Daniels; Susan Kadlubar
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

3.  Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients.

Authors:  Carla Miranda; Macarena Galleguillos; Roberto Torres; Karla Tardón; Dante D Cáceres; Kuen Lee; María A Redal; Nelson M Varela; Luis A Quiñones
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

4.  Sulfotransferase SULT1A1 Arg213His polymorphism with cancer risk: a meta-analysis of 53 case-control studies.

Authors:  Juanjuan Xiao; Yabiao Zheng; Yinghui Zhou; Ping Zhang; Jianguo Wang; Fangyuan Shen; Lixia Fan; Vijay Kumar Kolluri; Weiping Wang; Xiaolong Yan; Minghua Wang
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

5.  Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China.

Authors:  Yuliang Wang; Linna Peng; Hongyan Lu; Zhanhao Zhang; Shishi Xing; Dandan Li; Chunjuan He; Tianbo Jin; Li Wang
Journal:  Pharmgenomics Pers Med       Date:  2021-12-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.